Evaluation of a Novel Anti-Mucin 1 (MUC1) Antibody (PankoMab) as a Potential Diagnostic Tool in Human Ductal Breast Cancer; Comparison with Two Established Antibodies

Dian, Darius; Kühn, Christina; Mayr, Doris; Karsten, Uwe; Mylonas, Ioannis; Friese, Klaus; Jeschke, Udo

doi:10.1159/000209280

Cited by 22 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gd expression showed also a positive correlation with a tumour-associated epitope of MUC1 (TA-MUC1), which was stained by the PankoMabGEX™ antibody. This epitope was found to be steroid hormone receptor dependent in breast cancer [29]. Because it is known that Gd expression is also regulated by steroid hormones [30], there could be a common regulation pathway for both Gd and TA-MUC1.…”

Section: Discussionmentioning

confidence: 99%

Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients

et al. 2012

Self Cite

View full text Add to dashboard Cite

BackgroundGlycodelin is a cell surface glycoprotein offering a unique gender specific carbohydrate configuration. Sialylated carbohydrate structures, which are unusual for mammals, characterize Glycodelin isolated from amniotic fluid (Glycodelin A, GdA). Glycodelin in general exerts multiple, partly opposing functions ranging from immunosuppression to cell differentiation. As these markedly influence tumorigenesis, this study aimed to clarify whether expression of different Glycodelin isoforms is related to clinicopathological characteristics and prognosis of ovarian cancer patients. Further the use of Glycodelin as a serum marker in benign and malignant ovarian diseases was evaluated.MethodsOvarian cancer specimens (n = 152) were stained for Glycodelin with carbohydrate and peptide specific antibodies. Associations between Glycodelin expression and histological grading, FIGO stage as well as patient’s prognosis were examined. Glycodelin was correlated to expression of gonadotropin receptors and mucin-1, which are discussed as ovarian cancer tissue markers. In addition, Glycodelin serum concentrations were analyzed in patients suffering from benign (n = 73) or malignant (n = 38) ovarian neoplasias.ResultsGlycodelin A was found to be an independent prognostic marker for poor prognosis in advanced ovarian cancer patients. GdA staining correlated with gonadotropin receptor (FSHR and LHCGR) and with hCG expression. Gd expression showed a positive correlation with a tumour-associated epitope of mucin 1 (TA-MUC1). Further, compared to ovarian cancer, serum Gd was increased in patients with benign ovarian tumors.ConclusionGlycodelin A might be related to tumor aggressiveness and poor clinical outcome in advanced epithelial ovarian cancer. Glycodelin serum levels found in patients suffering from benign ovarian tumors, might contribute to a more global attenuation during progression of these precursor lesions.

show abstract

Section: Discussionmentioning

confidence: 99%

Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients

et al. 2012

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a previous paper, PankoMab was examined in patients with breast cancer in comparison with two other known antibodies. PankoMab was unique to the effect that its staining was correlated with the estrogen receptor expression [20]. …”

Section: Introductionmentioning

confidence: 99%

Multicentric and multifocal versusunifocal breast cancer: differences in the expression of E-cadherin suggest differences in tumor biology

et al. 2013

Self Cite

View full text Add to dashboard Cite

BackgroundThe aim of this study was to evaluate the expression of the cell adhesion-related glycoproteins MUC-1, β-catenin and E-cadherin in multicentric/multifocal breast cancer in comparison to unifocal disease in order to identify potential differences in the biology of these tumor types.MethodsA retrospective analysis was performed on the expression of MUC1, β-catenin and E-cadherin by immunohistochemistry on tumor tissues of a series of 112 breast cancer patients (total collective) treated in Munich between 2000 and 2002. By matched-pair analysis, 46 patients were entered into two comparable groups of 23 patients after categorizing them as having multicentric/multifocal or unifocal breast cancer. Matching criteria were tumor size, histology grade and lymph node status; based on these criteria, patients were distributed equally between the two groups (p = 1.000 each). Data were analyzed with the Kruskal-Wallis and the Mann–Whitney tests.ResultsIn the matched groups, we found a significantly down-regulated expression of E-cadherin in multicentric/multifocal breast cancer compared to unifocal disease (p = 0.024). The total collective showed even higher significance with a value of p < 0.0001. In contrast, no significant differences were observed in the expression of β-catenin between multicentric/multifocal and unifocal tumors (p = 0.636 and p = 0.914, respectively). When comparing the expression of MUC1, E-cadherin and β-catenin within the unifocal group, we found a significant positive correlation between E-cadherin and β-catenin (p = 0.003). In the multicentric/multifocal group we observed, in contrast to the unifocal group, a significant decrease of MUC1 expression with increased grading (p = 0.027).ConclusionThis study demonstrates that multicentric/multifocal and unifocal breast cancers with identical TNM-staging clearly differ in the expression level of E-cadherin. We suggest that the down-regulation of E-cadherin in multicentric/multifocal breast cancer is causally connected with the worse prognosis of this tumor type.

show abstract

“…Interestingly, in this article [11] we see completely different IHC staining patterns in two antibodies, DF3 and Vu-4-H5,whichtheoreticallyareagainstthesameepitope.Thisis consistentwiththepreviousexperiencethatweobtainedfrom SanDiegoInternationalWorkshop-everyMUC1antibody hasitsowncharacteristicstaining [15].…”

Section: Introductionmentioning

confidence: 61%

“…In this issue of OnkOlOgie, Dian and colleagues investigate the role of PankoMab as a diagnostic tool in breast cancer andcompareitsusewith2otherantibodies [11].Thereareat least56antibodiesfortheMUC1antigen,ofwhichthe2most commonly used -DF3 and Vu-4-H5 -were compared with PankoMab [11].Therationaleforchoosingtheseantibodiesis notexplainedinthearticle.DF3ismorecommonlyusedfor serum assays than for immunohistochemical staining, which mayexplainwhythatantibodydidnotcorrelatewithanyof thewell-knownclinicopathologicvariables.…”

Section: The Role Of Pankomab In Breast Cancermentioning

confidence: 99%

Where Do We Place PankoMab in the Reagents Used to Study the MUC1 Superfamily?

Li¹,

Sullivan²,

Harris³

2009

Onkologie

View full text Add to dashboard Cite

Evaluation of a Novel Anti-Mucin 1 (MUC1) Antibody (PankoMab) as a Potential Diagnostic Tool in Human Ductal Breast Cancer; Comparison with Two Established Antibodies

Cited by 22 publications

References 31 publications

Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients

Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients

Multicentric and multifocal versusunifocal breast cancer: differences in the expression of E-cadherin suggest differences in tumor biology

Where Do We Place PankoMab in the Reagents Used to Study the MUC1 Superfamily?

Contact Info

Product

Resources

About